CH 223191: Precision Aryl Hydrocarbon Receptor Antagonist for Environmental Toxicology and Intestinal Regeneration Research

Principle Overview: Targeting AhR Signaling with CH 223191

CH 223191 is a potent, selective antagonist of the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor central to the cellular response to environmental toxins such as dioxins. By inhibiting AhR-mediated transcription—specifically, TCDD-induced activation with an IC₅₀ of ~30 nM in cell-based assays (product_spec)—CH 223191 provides a critical tool for decoding the molecular underpinnings of toxicant-induced gene expression, immune modulation, and tissue regeneration. Its validated purity (>98% by HPLC and NMR) and reliable performance in both in vitro and in vivo systems position it as a workhorse for studies on dioxin toxicity mechanisms, hepatic injury models, and regenerative signaling in the gut epithelium.

Step-by-Step Workflow: Deploying CH 223191 in Experimental Systems

Whether interrogating cytochrome P450 1A1 expression, probing the microbiota–tryptophan–AhR axis, or modeling TCDD-induced toxicity, optimal use of CH 223191 requires careful consideration of solubility, dosing, and assay design. Here’s a practical, literature-informed workflow:

• Stock Preparation: Dissolve CH 223191 at ≥33.3 mg/mL in DMSO for maximal solubility. For lower concentrations or in vivo applications, ethanol can be used up to 2.31 mg/mL (product_spec).
• In Vitro Assays: Pre-treat cells with CH 223191 at 30–100 nM for 30–60 minutes prior to TCDD exposure to achieve robust AhR pathway inhibition (paper).
• In Vivo Toxicology: For mouse models, administer CH 223191 via intraperitoneal injection at doses ranging from 1 to 10 mg/kg, timed 1 hour before toxin (e.g., TCDD or DSS) challenge. Adjust vehicle volume to ensure solubilization and minimize DMSO or ethanol content per institutional guidelines (paper).
• Gene Expression Analysis: Quantify downstream targets (e.g., Cyp1a1, IL-22) by RT-qPCR or Western blot 6–24 hours post-treatment.
• Functional Readouts: For intestinal regeneration, combine CH 223191 with lineage tracing (Lgr5, MUC2, LYZ, ChgA markers) and histological scoring to differentiate effects on stem cell fate and epithelial repair (paper).

Protocol Parameters

• cell-based AhR pathway inhibition assay | 30–100 nM CH 223191, 30–60 min pre-treatment | in vitro, adherent mammalian cells | Achieves near-complete blockade of TCDD-induced reporter activation | paper
• in vivo AhR antagonism (mouse) | 1–10 mg/kg intraperitoneal injection, 1 hr pre-toxin | acute hepatic or intestinal injury models | Reduces Cyp1a1 upregulation and mitigates TCDD-induced toxicity | paper
• stock solution stability | <24 hours at room temperature, use immediately after dilution | all assay types | Prevents compound degradation, ensures reproducible inhibition | product_spec

Key Innovation from the Reference Study

The landmark study by Li et al. (2026) (paper) introduced a paradigm-shifting workflow that integrates host-microbiota interactions, tryptophan metabolic profiling, and AhR pathway manipulation to unravel mechanisms of mucosal repair in ulcerative colitis. By deploying an AhR inhibitor analogous to CH 223191, the researchers demonstrated that blockade of AhR not only abrogates the therapeutic benefits of microbiota-derived indole metabolites but also suppresses intestinal stem cell (ISC) differentiation toward functional epithelial lineages. Practically, this translates to:

• Pairing CH 223191 with fecal metabolomics to causally link microbial metabolites to AhR-driven gene networks.
• Using lineage-specific reporters (Lgr5, MUC2, LYZ, ChgA) to quantitatively assess stem cell fate decisions in response to AhR antagonism.
• Applying CH 223191 to dissect the contribution of the microbiota–tryptophan–AhR axis in tissue regeneration and barrier function restoration.

This integrative approach is especially valuable for researchers aiming to separate the direct effects of environmental toxins from the indirect modulation of host-microbiota crosstalk.

Advanced Applications and Comparative Advantages

CH 223191’s robust, nanomolar potency and selectivity make it uniquely suited for both foundational and translational research:

• Environmental Toxicology: Dissects dioxin toxicity mechanisms by suppressing Cyp1a1 expression and attenuating TCDD-induced hepatic and intestinal injury (paper).
• Regenerative Biology: Enables precise manipulation of AhR signaling in intestinal organoid and stem cell differentiation models, directly informing mucosal repair strategies (paper).
• Microbiota–Metabolite–Host Interaction: Integrates seamlessly with metabolomics, germ-free animal models, and transcriptomic profiling to map causal axes in inflammation and regeneration (paper).

Compared to older non-selective antagonists, CH 223191 minimizes off-target effects, is validated in both cell-based and animal studies, and offers greater reproducibility in dose-response and pathway selectivity (paper).

For researchers seeking a trusted supplier, APExBIO's CH 223191 stands out for its documented purity, lot-to-lot consistency, and application-specific solubility guidance.

Interlinking Related Resources: Context and Extension

• CH 223191: A Next-Generation AhR Antagonist for Advanced ... complements this workflow by outlining mechanistic insights and offering deeper context for toxicology-driven applications.
• CH 223191: Strategic AhR Antagonism in Regenerative & Toxicology Research extends the discussion into regenerative medicine, highlighting protocol nuance and translational promise beyond environmental exposure models.
• CH 223191: Precision AhR Antagonist for Toxicology & Stem Cell Studies provides protocol benchmarking and comparative analyses, underscoring CH 223191’s competitive edge in both toxicology and stem cell differentiation workflows.

Troubleshooting and Optimization Tips

• Solubility Issues: If precipitation occurs in aqueous buffers, revert to DMSO or ethanol stocks and ensure final solvent concentration does not exceed cytotoxic thresholds (≤0.1% v/v for DMSO in cell culture; workflow_recommendation).
• Compound Stability: Prepare fresh CH 223191 solutions prior to each experiment; avoid storing diluted solutions beyond 24 hours to maintain potency (product_spec).
• Off-Target Effects: Validate specificity by including TCDD and vehicle controls, and confirm AhR pathway inhibition via downstream target suppression (e.g., Cyp1a1, IL-22) (paper).
• Dose Optimization: Titrate CH 223191 concentration for each cell line or animal model, as sensitivity to AhR inhibition can vary (paper).
• Microbiota-Linked Assays: In germ-free or antibiotic-treated models, interpret results with caution, as the absence of microbial metabolites may confound AhR inhibition outcomes (paper).

Future Outlook: CH 223191 in Precision Toxicology and Regenerative Therapies

Recent advances, epitomized by the Li et al. (2026) study, have illuminated a novel “microbiota–tryptophan metabolism–AhR–ISC differentiation” axis that governs epithelial regeneration and mucosal barrier repair. CH 223191 is poised to drive the next era of research in this field by enabling targeted dissection of AhR-mediated processes in both environmental toxicology and regenerative medicine. As protocols become increasingly integrated—leveraging multi-omics, advanced imaging, and lineage tracing—CH 223191’s specificity and reliability will remain indispensable for unraveling complex host-microbe-toxin interactions and for screening new therapeutic interventions (paper).

With APExBIO providing validated CH 223191 for diverse research needs, investigators are empowered to bridge mechanistic insight with translational impact, ensuring reproducibility and rigor at every step.